PMO Interview with the Innovator Series: Volume 5Video Categories: PMO Interview with the Innovator Series
Michael Pellini, President and Chief Executive Officer of Foundation Medicine, offers a definition of personalized medicine in this new video series from Personalized Medicine in Oncology.
Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
Dr Wainberg and Dr Gerson talk about the results of using investigational agent BBI608 combined with another drug that is used as a standard of care.